Clinical practice guidelines on iron therapy: A critical evaluation.

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Anemia is a common complication in chronic kidney disease (CKD) patients.
• Erythropoiesis-stimulating agents (ESA) and iron therapy are primary treatments for CKD anemia.
• Intravenous (IV) iron administration is increasing globally due to ESA concerns and cost factors.

Purpose of the Study:

• To review current guidelines and evidence regarding iron therapy in CKD patients.
• To highlight areas of consensus and debate in IV iron administration.
• To inform clinical practice on the safe and effective use of iron in CKD.

Main Methods:

• Review of existing guidelines and position papers on iron therapy in nephrology.
• Analysis of current evidence concerning IV iron efficacy and safety in CKD.
• Synthesis of recommendations from international bodies and societies.

Main Results:

• General agreement exists for iron therapy in iron-deficient CKD patients.
• IV iron may improve hemoglobin, delay ESA initiation, and reduce ESA dosage.
• Significant debate surrounds IV iron safety and efficacy with high ferritin levels and during infections.

Conclusions:

• Current recommendations for IV iron in CKD are not uniform due to limited evidence.
• Oral iron should be considered first, particularly for non-dialysis CKD patients.
• Administration of IV iron requires caution, especially during infections, and necessitates emergency preparedness.